Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
暂无分享,去创建一个
G. Stone | S. Ellis | D. Cohen | D. Kereiakes | Y. Lei | E. Magnuson | S. Baron | Khaja M. Chinnakondepalli | Katherine A. Vilain